Éric Durot

969 total citations
26 papers, 92 citations indexed

About

Éric Durot is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Éric Durot has authored 26 papers receiving a total of 92 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pathology and Forensic Medicine, 16 papers in Genetics and 8 papers in Oncology. Recurrent topics in Éric Durot's work include Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Cutaneous lymphoproliferative disorders research (6 papers). Éric Durot is often cited by papers focused on Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Cutaneous lymphoproliferative disorders research (6 papers). Éric Durot collaborates with scholars based in France, United States and United Kingdom. Éric Durot's co-authors include Alain Delmer, Véronique Leblond, Quoc‐Hung Le, Stéphane Leprêtre, Anne‐Sophie Michallet, Anne Quinquenel, Cécile Tomowiak, Efstathios Kastritis, Christine Hoeffel and Stephen M. Ansell and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Éric Durot

21 papers receiving 92 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Éric Durot France 6 74 65 22 21 16 26 92
Elżbieta Iskierka‐Jazdzewska Poland 7 84 1.1× 71 1.1× 26 1.2× 36 1.7× 21 1.3× 25 110
Tommi Salmi United States 5 75 1.0× 86 1.3× 23 1.0× 17 0.8× 24 1.5× 11 96
Gayane Tumyan Russia 5 75 1.0× 56 0.9× 22 1.0× 60 2.9× 10 0.6× 22 117
John M. Pagel United States 6 70 0.9× 77 1.2× 17 0.8× 25 1.2× 20 1.3× 20 96
Anouk de Jong United States 5 66 0.9× 99 1.5× 26 1.2× 17 0.8× 39 2.4× 7 116
Yaroslav Kulyaba United Kingdom 6 70 0.9× 74 1.1× 37 1.7× 28 1.3× 8 0.5× 9 98
Yufu Lin China 3 35 0.5× 50 0.8× 28 1.3× 22 1.0× 18 1.1× 10 81
S. Stilgenbauer Germany 5 50 0.7× 56 0.9× 27 1.2× 18 0.9× 10 0.6× 19 71
M Asuncion Echeveste Spain 3 46 0.6× 61 0.9× 16 0.7× 8 0.4× 29 1.8× 4 75
Ganna Usenko Ukraine 3 61 0.8× 71 1.1× 22 1.0× 18 0.9× 30 1.9× 14 84

Countries citing papers authored by Éric Durot

Since Specialization
Citations

This map shows the geographic impact of Éric Durot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Durot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Durot more than expected).

Fields of papers citing papers by Éric Durot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Durot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Durot. The network helps show where Éric Durot may publish in the future.

Co-authorship network of co-authors of Éric Durot

This figure shows the co-authorship network connecting the top 25 collaborators of Éric Durot. A scholar is included among the top collaborators of Éric Durot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éric Durot. Éric Durot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hueso, Thomas, Grégory Lazarian, Adrien Chauchet, et al.. (2025). Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real‐World Analysis. eJHaem. 6(2). e70019–e70019.
2.
Kapoor, Prashant, Meletios Α. Dimopoulos, Stephen M. Ansell, et al.. (2025). Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease. Seminars in Hematology. 62(2). 90–105. 1 indexed citations
3.
Durot, Éric, Jithma P. Abeykoon, Damien Roos‐Weil, et al.. (2025). Report of Consensus Panel 6 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on Diagnosis and Management of Transformed Waldenstrom's Macroglobulinemia. Seminars in Hematology. 62(2). 120–125. 1 indexed citations
4.
Roos‐Weil, Damien, Cécile Tomowiak, Stéphanie Poulain, et al.. (2025). Waldenström’s macroglobulinemia: The LYSA pragmatic guidelines. European Journal of Cancer. 232. 116120–116120.
5.
6.
Durot, Éric, Damien Roos‐Weil, Adrien Chauchet, et al.. (2024). High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia. Blood. 143(26). 2804–2807. 3 indexed citations
7.
Talaulikar, Dipti, Cécile Tomowiak, Elise Toussaint, et al.. (2023). Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America. 37(4). 787–799. 3 indexed citations
8.
Durot, Éric & Alain Delmer. (2023). Born in the UK: A registry to improve and broadcast knowledge on Waldenström macroglobulinaemia. British Journal of Haematology. 201(5). 809–810. 1 indexed citations
9.
Durot, Éric, Sebastien Mulé, David Morland, et al.. (2023). Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance. Diagnostics. 13(13). 2237–2237. 3 indexed citations
10.
Durot, Éric & Cécile Tomowiak. (2023). Advances in Treatment of Waldenström Macroglobulinemia. Current Oncology Reports. 25(11). 1375–1386. 1 indexed citations
11.
Kanagaratnam, Lukshe, David Morland, Amandine Durand, et al.. (2023). Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab. HemaSphere. 7(5). e861–e861. 7 indexed citations
12.
Durot, Éric, Cécile Tomowiak, Elise Toussaint, et al.. (2022). Transformed Waldenström Macroglobulinemia: Update on Diagnosis, Prognosis and Treatment. SHILAP Revista de lepidopterología. 3(4). 650–662. 1 indexed citations
13.
Durlach, A., et al.. (2022). Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas. Acta Dermato Venereologica. 102. adv00676–adv00676. 2 indexed citations
14.
Maloisel, Frédéric, et al.. (2022). Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma. Journal of Cancer Research and Clinical Oncology. 149(5). 1883–1893. 3 indexed citations
15.
Labreuche, Julien, Éric Durot, Cécile Tomowiak, et al.. (2022). Does early disease progression predict survival after first line‐treatment of Waldenström macroglobulinemia?. Hematological Oncology. 40(3). 400–408. 5 indexed citations
16.
Morland, David, et al.. (2021). 18F-FDG cerebellum/liver index as a prognostic factor for progression-free survival in diffuse large B-cell lymphoma. Annals of Nuclear Medicine. 35(7). 785–793. 2 indexed citations
17.
18.
Durot, Éric, et al.. (2018). Skeletal involvement of hairy cell leukemia. Clinical Case Reports. 6(8). 1651–1652. 6 indexed citations
19.
Durot, Éric, Cécile Tomowiak, Anne‐Sophie Michallet, et al.. (2016). Retrospective Analysis of 56 Cases of Transformed Waldenström Macroglobulinemia. a Study on Behalf of the French Innovative Leukemia Organization (FILO). Blood. 128(22). 2982–2982. 4 indexed citations
20.
Durot, Éric, Anne‐Sophie Michallet, Stéphane Leprêtre, et al.. (2014). Platinum and high‐dose cytarabine‐based regimens are efficient in ultra high/high‐risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study. European Journal Of Haematology. 95(2). 160–167. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elżbieta Iskierka‐Jazdzewska Breakdown of academic impact, for papers by Tommi Salmi Breakdown of academic impact, for papers by Gayane Tumyan Breakdown of academic impact, for papers by John M. Pagel Breakdown of academic impact, for papers by Anouk de Jong Breakdown of academic impact, for papers by Yaroslav Kulyaba Breakdown of academic impact, for papers by Yufu Lin Breakdown of academic impact, for papers by S. Stilgenbauer Breakdown of academic impact, for papers by M Asuncion Echeveste Breakdown of academic impact, for papers by Ganna Usenko
Rankless by CCL
2026